文献速递淋巴瘤造血干细胞移植与细胞治疗

糖皮质激素对大B细胞淋巴瘤CAR-T疗效的预后影响

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
PubMed 文献 · Blood · 2021-01-01

该研究评估糖皮质激素的剂量、疗程和启用时机对复发或难治性大B细胞淋巴瘤患者接受标准抗CD19 CAR-T治疗后临床结局的影响。100例可评估患者中60例(60%)因处理CAR-T相关毒性而使用糖皮质激素。中位随访10个月(95%CI,8-12个月)后,较高累积剂量与更短无进展生存期相关,较高累积剂量、较长疗程及CAR-T输注后早期使用与更短总生存期相关。

要点

  • 较高累积剂量糖皮质激素与更短无进展生存期显著相关。
  • 较高累积剂量、较长疗程及早期使用糖皮质激素与更短总生存期显著相关。
  • 处理CAR-T相关毒性时,应尽可能使用最低剂量、最短疗程并延迟启用。

核心结论

  • 较高累积剂量糖皮质激素与更短无进展生存期显著相关。
  • 较高累积剂量、较长疗程及CAR-T输注后早期使用糖皮质激素与更短总生存期显著相关。
  • 处理CAR-T相关毒性时,糖皮质激素应使用最低剂量、最短疗程,并在临床可行时延迟启用。

研究设计与样本

  • 回顾性评估接受标准抗CD19 CAR-T治疗的复发或难治性大B细胞淋巴瘤患者,共100例可评估。
  • 60例(60%)因CAR-T相关毒性接受糖皮质激素治疗。
  • 中位累积地塞米松等效剂量186 mg(范围8-1803),中位疗程9天(范围1-30)。
  • 45例(75%)在CAR-T输注后第0至7天启用糖皮质激素,15例(25%)在第7天后启用。
  • 中位随访10个月(95%CI,8-12个月)。

主要发现

  • 较高累积剂量糖皮质激素与显著更短的无进展生存期相关。
  • 较高累积剂量糖皮质激素与显著更短的总生存期相关。
  • 较长疗程糖皮质激素与显著更短的总生存期相关。
  • CAR-T输注后早期使用糖皮质激素与显著更短的总生存期相关。

临床怎么用

  • 处理CAR-T相关毒性时,糖皮质激素应尽可能使用最低剂量和最短疗程。
  • 临床可行时应延迟糖皮质激素启用,以减少对CAR-T疗效的不利影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may affect clinical efficacy. Here, we determined the impact of corticosteroids on clinical outcomes in patients with relapsed or refractory large B-cell lymphoma treated with standard of care anti-CD19 CAR T-cell therapy. Among 100 patients evaluated, 60 (60%) received corticosteroids for management of CAR T-cell therapy-associated toxicities. The median cumulative dexamethasone-equivalent dose was 186 mg (range, 8-1803) and the median duration of corticosteroid treatment was 9 days (range, 1-30). Corticosteroid treatment was started between days 0 and 7 in 45 (75%) patients and beyond day 7 in 15 (25%). After a median follow-up of 10 months (95% confidence interval, 8-12 months), use of higher cumulative dose of corticosteroids was associated with significantly shorter progression-free survival. More importantly, higher cumulative dose of corticosteroids, and prolonged and early use after CAR T-cell infusion were associated with significantly shorter overall survival. These results suggest that corticosteroids should be used at the lowest dose and for the shortest duration and their initiation should be delayed whenever clinically feasible while managing CAR T-cell therapy-associated toxicities.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021. PMID: 33534891. doi:10.1182/blood.2020008865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。